PARP1 and cancer: Firstly, PARP-1 inhibitors compete with the binding site of NAD+ in the catalytic domain of PARP-1 enzymes and inhibit their activity, leading to an increased error in repair of DNA, particularly in rapidly dividing cancer cells [10].